rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RADX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Director Bruce Goodwin Discloses Indirect Share Sales

      Tipranks Press Release.

      Nov 12The Globe and MailRADX
      Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases

      Single, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity above prespecified performance thresholds Radiopharm Theranostics advancing preparations for Phase 3 study with clinical supply of 18F-labeled RAD101 from partnership with Siemens Healthineers Company expects to complete CRO selection in the fourth quarter 2026, initiate site activations and begin dosing patients in first half 2027 SYDNEY, Nov. 04, 202

      Nov 4Yahoo FinanceRADX
      Radiopharm Theranostics Reports Business Update
      Nov 2Yahoo FinanceRADX
      Perceptive Discovery Launches Astatine-211 Study Capabilities in the US and UK
      Oct 16Yahoo FinanceRADX
      Perceptive Discovery and Nucleus RadioPharma Announce Strategic Partnership to Accelerate Radiopharmaceutical Development from Target to Clinic
      Oct 9Yahoo FinanceRADX
      Radiopharm completes FDA meeting on brain imaging agent RAD101
      Oct 5Investing.comRADX
      Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

      Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging Currently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in next 30 days SYDNEY, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage radiopharmaceutical company, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S.

      Oct 5Yahoo FinanceRADX
      Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

      RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint Meeting with FDA planned on October 1st to align on RAD101Phase 3 pivotal trial protocol Brain Metastases Imaging has ~$600 million total addressable market, and there are no currently approved PET products SYDNEY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on

      Sep 14Yahoo FinanceRADX
      Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

      Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting potential of RAD301 and continuation of its clinical development SYDNEY, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceutical

      Sep 9Yahoo FinanceRADX
      Radiopharm doses first patient in second cohort of RV-01 trial
      Aug 26Investing.comRADX
      Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

      Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company’s joint venture with MD Anderson Cancer CenterSYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has dosed the first patient in the second cohort of its

      Aug 26Yahoo FinanceRADX

      This is the newest page. Registered accounts read further back.